ATE399011T1 - Substituierte diketopiperazine als oxytocin- antagonisten - Google Patents

Substituierte diketopiperazine als oxytocin- antagonisten

Info

Publication number
ATE399011T1
ATE399011T1 AT02799077T AT02799077T ATE399011T1 AT E399011 T1 ATE399011 T1 AT E399011T1 AT 02799077 T AT02799077 T AT 02799077T AT 02799077 T AT02799077 T AT 02799077T AT E399011 T1 ATE399011 T1 AT E399011T1
Authority
AT
Austria
Prior art keywords
oxytocin antagonists
substituted diketopiperazine
oxytocin
diketopiperazine
substituted
Prior art date
Application number
AT02799077T
Other languages
English (en)
Inventor
Alan Borthwick
Richard Hatley
Deirdre HICKEY
John Liddle
David Livermore
Andrew Mason
Neil Miller
Fabrizio Nerozzi
Steven Sollis
Anna Szardenings
Paul Wyatt
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE399011T1 publication Critical patent/ATE399011T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02799077T 2001-12-21 2002-12-20 Substituierte diketopiperazine als oxytocin- antagonisten ATE399011T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0130677.8A GB0130677D0 (en) 2001-12-21 2001-12-21 Medicaments and novel compounds

Publications (1)

Publication Number Publication Date
ATE399011T1 true ATE399011T1 (de) 2008-07-15

Family

ID=9928187

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02799077T ATE399011T1 (de) 2001-12-21 2002-12-20 Substituierte diketopiperazine als oxytocin- antagonisten

Country Status (27)

Country Link
US (3) US7514437B2 (de)
EP (1) EP1458393B1 (de)
JP (1) JP4638149B2 (de)
KR (2) KR100997856B1 (de)
CN (1) CN100374115C (de)
AT (1) ATE399011T1 (de)
AU (1) AU2002364304B2 (de)
BR (1) BRPI0215277B1 (de)
CA (1) CA2471355C (de)
CO (1) CO5590916A2 (de)
CY (1) CY1108334T1 (de)
DE (1) DE60227283D1 (de)
DK (1) DK1458393T3 (de)
ES (1) ES2307827T3 (de)
GB (1) GB0130677D0 (de)
HU (1) HU229708B1 (de)
IL (2) IL162515A0 (de)
IS (1) IS2613B (de)
MX (1) MXPA04006033A (de)
NO (1) NO329543B1 (de)
NZ (1) NZ533218A (de)
PL (1) PL215826B1 (de)
PT (1) PT1458393E (de)
RU (1) RU2303032C2 (de)
SI (1) SI1458393T1 (de)
WO (1) WO2003053443A1 (de)
ZA (1) ZA200404326B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
RU2318818C1 (ru) * 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
CA2716347C (en) 2008-02-21 2017-06-20 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
MX339300B (es) * 2008-08-22 2016-05-19 British Columbia Cancer Agency Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos.
JP2013509391A (ja) 2009-10-30 2013-03-14 グラクソ グループ リミテッド (3r,6r)−3−(2,3−ジヒドロ−1h−インデン−2−イル)−1−[(1r)−1−(2,6−ジメチル−3−ピリジニル)−2−(4−モルホリニル)−2−オキソエチル]−6−[(1s)−1−メチルプロピル]−2,5−ピペラジンジオンの新規結晶性形態
CN103189384A (zh) * 2010-10-29 2013-07-03 隆萨有限公司 形成二酮哌嗪的二肽连接子
CN103242246A (zh) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 3-位取代的n-甲基哌嗪的合成方法
CN105061317B (zh) * 2015-08-26 2017-08-25 浙江大果生物医药科技有限公司 一类吲唑盐类化合物及其制备方法和应用
SG10202009723PA (en) 2016-01-04 2020-11-27 ObsEva SA Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN109305969B (zh) * 2017-07-27 2023-03-10 江苏恒瑞医药股份有限公司 哌嗪-2,5-二酮类衍生物、其制备方法及其在医药上的应用
CN109485598A (zh) * 2018-11-29 2019-03-19 河南师范大学 一种去除氨基上喹啉保护基的新方法
US20220323410A1 (en) 2019-09-03 2022-10-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN115380122A (zh) 2020-02-10 2022-11-22 奥布赛瓦股份公司 用于催产素受体拮抗剂疗法的生物标志物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) * 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
HUT67287A (en) * 1991-09-13 1995-03-28 Merck & Co Inc Piperazynil camphor derivatives and pharmaceutical compositions containing them
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
GB2326639A (en) 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
GB9713748D0 (en) * 1997-06-27 1997-09-03 Unilever Plc Production of detergent granulates
YU47600A (sh) 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
EP1051397B1 (de) 1998-01-29 2008-12-31 Aventis Pharmaceuticals Inc. Verfahren zur herstellung einer n-¬(aliphathisch oder aromatisch)carbonyl -2-aminoacetamid-verbindung und einer cyclischen verbindung
EP1070084A4 (de) * 1998-03-16 2001-09-12 Ontogen Corp Piperazine als inhibitoren der fruktose-1,6-bisphosphatase (fbpase)
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414092D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
AU2002364304A1 (en) 2003-07-09
DK1458393T3 (da) 2008-10-13
EP1458393A1 (de) 2004-09-22
US7514437B2 (en) 2009-04-07
NO329543B1 (no) 2010-11-08
PL370981A1 (en) 2005-06-13
NO20043115L (no) 2004-07-20
HK1069339A1 (en) 2005-05-20
IL162515A (en) 2012-08-30
CY1108334T1 (el) 2014-02-12
KR100997856B1 (ko) 2010-12-01
US8541579B2 (en) 2013-09-24
CN100374115C (zh) 2008-03-12
HU229708B1 (en) 2014-05-28
RU2303032C2 (ru) 2007-07-20
CN1606443A (zh) 2005-04-13
NZ533218A (en) 2007-01-26
US20050148572A1 (en) 2005-07-07
JP4638149B2 (ja) 2011-02-23
BRPI0215277B1 (pt) 2016-05-03
US20090186867A1 (en) 2009-07-23
DE60227283D1 (de) 2008-08-07
CA2471355A1 (en) 2003-07-03
PT1458393E (pt) 2008-09-29
KR20040065285A (ko) 2004-07-21
WO2003053443A1 (en) 2003-07-03
IL162515A0 (en) 2005-11-20
ES2307827T3 (es) 2008-12-01
EP1458393B1 (de) 2008-06-25
HUP0500136A2 (hu) 2005-05-30
US20130131338A1 (en) 2013-05-23
ZA200404326B (en) 2005-09-28
AU2002364304B2 (en) 2008-04-17
PL215826B1 (pl) 2014-01-31
GB0130677D0 (en) 2002-02-06
CA2471355C (en) 2013-04-23
BR0215277A (pt) 2004-12-14
US8367673B2 (en) 2013-02-05
MXPA04006033A (es) 2004-09-27
JP2005517663A (ja) 2005-06-16
CO5590916A2 (es) 2005-12-30
IS7315A (is) 2004-06-16
KR20100060012A (ko) 2010-06-04
SI1458393T1 (sl) 2008-10-31
IS2613B (is) 2010-04-15
RU2004122392A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
DE60227283D1 (de) Substituierte diketopiperazine als oxytocin-antagonisten
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
CY1107853T1 (el) Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
BG66085B1 (bg) Фенилаланинови производни
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
SE9902267D0 (sv) New compounds
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
EA200201232A1 (ru) Производные сульфонамида
SE0004827D0 (sv) Therapeutic compounds
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
ATE366720T1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
SE0002353D0 (sv) New use
SE0100873D0 (sv) Method of treatment
ATE288254T1 (de) Methode zur behandlung von schlaganfall
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
EA200200846A1 (ru) Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1458393

Country of ref document: EP